Improving Efficiency in Upstream Process Development
01st March 2021 | 10:00 am EST | Jackie Gonzalez, Senior Upstream Development Engineer at Takeda, Klaus Mauch, CEO at Insilico Biotechnology AG |WATCH FOR FREE
The time required to develop and produce a new molecule and put it in the hands of patients is an important consideration in the drug development process. The utilization of novel tools, such as high-throughput systems and modeling allows for increased and more targeted development, ultimately reducing timelines and costs. Here, we demonstrate the application and impact of these tools on major activities in upstream process development.
Presented by Jackie Gonzalez, Senior Upstream Development Engineer at Takeda
Jackie Gonzalez is an upstream process engineer at Takeda Pharmaceuticals focusing on media development and high-throughput technologies. She holds a B.S. in chemical engineering from Cornell University and a Ph.D. in chemical engineering from the University of Delaware. Her previous experience focused on metabolic modeling and application of C-metabolic flux analysis in bacteria and CHO cells for optimization of cell culture processes.
Followed by Klaus Mauch, CEO at Insilico Biotechnology AG
Klaus Mauch is one of Insilico’s co-founders and became managing director in 2004 and CEO in 2006. In his previous role as CTO, he was responsible for the design and development of Insilico’s modeling and simulation platform where he established novel methods for the computer-aided construction of cellular networks. Before that, he gained extensive experience in metabolic engineering and applied systems biology as a group leader at the Institute of Biochemical Engineering, University of Stuttgart. He was awarded a Master’s degree in Chemical Engineering by the Technical University of Karlsruhe, Germany. Klaus is a member of the Advisory Board of the Division Systems Biology and Synthetic Biology of DECHEMA, a board member of the Industrial Association White Biotechnology (IWBio), and a board member of the Association of German Biotechnology Companies (VBU).
Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality, and process robustness. Groundbreaking predictive power is achieved by exploiting process data using machine learning and models of biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods, and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design, and process control. Founded in 2001, Insilico Biotechnology AG is a privately held company based in Stuttgart, Germany.